pulmonary embolism market

 

Key Highlights

 

As per the research study by Willich et al. (2018), empirical estimates of Pulmonary Embolism incidence rates, based on European cohort studies, range from 0.15 per 1000 population per year in Spain, 0.189 in Italy, 0.342 in the UK, to 0.60 in France. The rates vary partially depending on the setting of the study and the age of the study population. In contrast to population cohort studies, an incidence-based epidemiological model estimated that the Pulmonary Embolism incidence rate is 0.95 per 1000 population per year and the occurrence of Pulmonary Embolism events is almost a third of a million per year in the EU. 

 

The Pulmonary Embolism epidemiology covered in the report provides historical as well as forecasted epidemiology segmented as Total Incident Cases of Pulmonary Embolism, Gender-specific Cases of Pulmonary Embolism, Severity-specific Cases of Pulmonary Embolism, and Treated Cases of Pulmonary Embolism in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Request for unlocking the CAGR of the “Pulmonary Embolism Market”

 

DelveInsight’s “Pulmonary Embolism – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Pulmonary Embolism, historical and forecasted epidemiology as well as the Pulmonary Embolism market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom and Japan.

 

The Pulmonary Embolism market report provides current treatment practices, emerging drugs, the market share of individual therapies, and current and forecasted Pulmonary Embolism market size from 2019 to 2032, segmented by the seven major markets. The report also covers the current Pulmonary Embolism treatment practices/algorithms and Pulmonary Embolism unmet needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

 

Study period: 2019–2032

 

Pulmonary Embolism Market: Understanding and Treatment Algorithm

DelveInsight’s Pulmonary Embolism market report gives a thorough understanding of Pulmonary Embolism by including details such as disease definition, Pulmonary Embolism symptoms, causes, pathophysiology, diagnosis, and treatment. 

 

Pulmonary Embolism is a blockage within a pulmonary artery in the lungs. It is a common and potentially deadly form of venous thromboembolic disease. The most common cause of such a blockage is a blood clot that forms in a deep vein in the leg and travels to the lungs, where it gets lodged in a smaller lung artery. Almost all blood clots that cause Pulmonary Embolism are formed in the deep leg veins. Clots also can form in the deep veins of the arms or pelvis.

 

Pulmonary Embolism is also one of the most common causes of cardiovascular death and is associated with multiple inherited and acquired risk factors as well as advanced age. The populations at greatest risk of Pulmonary Embolism include those who had recent trauma, had recent major surgery, are obese, are pregnant, underwent hormonal therapy, smoke, and have certain cancers. 

 

Half the people who have Pulmonary Embolism have no symptoms. If they do have symptoms, they can include shortness of breath, chest pain, or coughing up blood. Pulmonary Embolism symptoms of a blood clot include warmth, swelling, pain, tenderness, and redness of the leg. 

 

Pulmonary Embolism Diagnosis

A diagnosis of Pulmonary Embolism is often difficult to diagnose because of the variable nature of the presentation of Pulmonary Embolism. The evaluation largely depends on the likelihood of Pulmonary Embolism and the stability of the patient. There are scoring systems to assist in the determination of the likelihood of Pulmonary Embolism and thromboembolic events. The diagnosis of a Pulmonary Embolism is achieved through clinical evaluation, laboratory testing such as brain natriuretic peptide (BNP) and troponin, electrocardiogram (EKG), pulmonary angiogram, radiologic examinations, and echocardiography.

 

Other tests include D-dimer levels test, CT (computed tomography) scan or CT angiogram, Magnetic resonance imaging (MRI), Doppler ultrasound, ventilation-perfusion scans, and pulmonary angiogram.

 

Pulmonary Embolism Treatment

Pulmonary Embolism Treatment is based on the severity, which is generally classified as massive (high risk), submassive (intermediate risk), or nonmassive (low risk). The purpose of treatment is to break up clots and help keep other clots from forming. Prompt treatment is essential to prevent serious complications or death.

 

Pulmonary Embolism Treatment with anticoagulants, or blood thinners, keep blood clots from getting larger and stop new clots from forming, while thrombolytics are medicines to dissolve blood clots. Depending on the severity of the blood clot and its effect on other organs a thrombolytic therapy, surgical embolectomy or interventional procedures may be performed to improve the blood flow. 

 

Other procedures include catheter-assisted thrombus removal which uses a flexible tube to reach a blood clot in the lung and a vena cava filter used in some people who cannot take blood thinners.

 

Pulmonary Embolism Epidemiology 

The Pulmonary Embolism epidemiology section provides insights into the historical and current Pulmonary Embolism patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Pulmonary Embolism report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

 

Key findings

 

According to a large-population, retrospective, cohort study by Clark et al. (2019), Pulmonary Embolism is a significant health concern, affecting mainly the adult and elderly population. The overall annual incidence of Pulmonary Embolism was 0.6 per 1,000. The incidence of Pulmonary Embolism was rare in the pediatric population at a rate of less than 1 out of 100,000 and relatively common after the age of 75 years at a rate of 1 out of 100. It should be noted that the actual incidence of Pulmonary Embolism was likely significantly higher as autopsy studies have shown that a premortem diagnosis had occurred in only 30%−45% of patients.

 

As per the research study by Willich et al. (2018), empirical estimates of Pulmonary Embolism incidence rates, based on European cohort studies, range from 0.15 per 1000 population per year in Spain, 0.189 in Italy, 0.342 in the UK, to 0.60 in France. The rates vary partially depending on the setting of the study and the age of the study population. In contrast to population cohort studies, an incidence-based epidemiological model estimated that the Pulmonary Embolism incidence rate is 0.95 per 1000 population per year and the occurrence of Pulmonary Embolism events is almost a third of a million per year in the EU. 

 

The Pulmonary Embolism epidemiology covered in the report provides historical as well as forecasted epidemiology segmented as Total Incident Cases of Pulmonary Embolism, Gender-specific Cases of Pulmonary Embolism, Severity-specific Cases of Pulmonary Embolism, and Treated Cases of Pulmonary Embolism in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Country-wise Pulmonary Embolism Epidemiology

The epidemiology segment also provides the Pulmonary Embolism epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Pulmonary Embolism Recent Developments

• In September 2025, 4D Medical received FDA 510(k) clearance for its CT VQ scan, the first non-contrast imaging tool providing quantitative ventilation and perfusion analysis from standard chest CTs. This technology aids in detecting pulmonary embolism, assessing CTEPH and other lung conditions, and supporting surgical planning.

Pulmonary Embolism Drug Chapters

The drug chapter segment of the Pulmonary Embolism report encloses a detailed analysis of Pulmonary Embolism marketed drugs and late-stage (Phase III and Phase II) Pulmonary Embolism pipeline drugs. It also helps understand the Pulmonary Embolism clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging Pulmonary Embolism Drugs

The report details the emerging Pulmonary Embolism therapies under the late and mid-stage of development for Pulmonary Embolism treatment.

 

Pulmonary Embolism Market Outlook

The Pulmonary Embolism market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Pulmonary Embolism market trends by analyzing the impact of current therapies on the market, Pulmonary Embolism unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the Pulmonary Embolism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Pulmonary Embolism market in the 7MM is expected to witness a major change in the study period 2019–2032.

 

Key findings

This section includes a glimpse of the Pulmonary Embolism market in the 7MM.

 

The United States: Pulmonary Embolism Market Outlook

This section provides the total Pulmonary Embolism market size and market size by therapies in the United States.

 

 

EU4 and the United Kingdom: Pulmonary Embolism Market Outlook

The total Pulmonary Embolism market size and market size by therapies in EU4 (Germany, France, Italy, and Spain) and the United Kingdom are provided in this section.

 

Japan: Pulmonary Embolism Market Outlook

The total Pulmonary Embolism market size and market size by therapies in Japan are also mentioned.

 

Pulmonary Embolism Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Embolism market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Pulmonary Embolism market uptake by drugs, patient uptake by therapies, and sales of each drug.  

 

This will help in understanding the Pulmonary Embolism drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

 

Pulmonary Embolism Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses the Pulmonary Embolism key players involved in developing targeted therapeutics.

 

Development Activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information on Pulmonary Embolism emerging therapies.

 

Pulmonary Embolism Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Pulmonary Embolism domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and Pulmonary Embolism emerging therapies and treatment patterns along with Pulmonary Embolism market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Pulmonary Embolism unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Pulmonary Embolism market by using various competitive intelligence tools that include – SWOT analysis and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Pulmonary Embolism Market Report

·         Descriptive overview of Pulmonary Embolism, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies.

·         Comprehensive insight into Pulmonary Embolism epidemiology and forecasts in the 7MM.

·         An all-inclusive account of both the current and Pulmonary Embolism emerging therapies, along with the assessment of new therapies, is expected to have an impact on the current treatment landscape.

·         Exhaustive analysis of the Pulmonary Embolism market; historical and forecasted covering drug outreach in the 7MM coverage.

·         Detailed patient-based Pulmonary Embolism market forecasting determines the trends shaping and driving the global Pulmonary Embolism market.

 

Pulmonary Embolism Market Report Highlights

·         In the coming years, the Pulmonary Embolism market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

·         The Pulmonary Embolism companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Embolism R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

·         Pulmonary Embolism Companies are involved in developing Pulmonary Embolism therapies. The launch of emerging therapies will significantly impact the Pulmonary Embolism market.

·         A better understanding of Pulmonary Embolism pathogenesis will also contribute to the development of novel therapeutics for Pulmonary Embolism.

·         Our in-depth analysis of the Pulmonary Embolism pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Pulmonary Embolism clinical trials profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Pulmonary Embolism Report Insights

·         Patient-Based Pulmonary Embolism Market Forecasting 

·         Therapeutic approaches

·         Pulmonary Embolism pipeline analysis

·         Pulmonary Embolism market size and trends

·         Pulmonary Embolism market opportunities

·         Impact of upcoming therapies

 

Pulmonary Embolism Report Key Strengths

·         10 years forecast

·         The 7MM Coverage

·         Pulmonary Embolism epidemiology segmentation

·         Key cross competition

·         KOL views

·         Pulmonary Embolism drugs uptake

 

Pulmonary Embolism Report Assessment

·         Current treatment practices

·         Unmet needs

·         Pulmonary Embolism pipeline product profiles

·         Pulmonary Embolism market attractiveness

 

Key Questions

 

Pulmonary Embolism market insights:

·         What would be the Pulmonary Embolism market growth till 2032, and what will be the resultant market size in 2032?

·         What was the Pulmonary Embolism drug class share (in percentage) distribution in 2019, and how would it look in 2032?

·         What would be the Pulmonary Embolism total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?

·         What are the key findings of the market across the 7MM, and which country will have the largest Pulmonary Embolism market size during the forecast period (2019–2032)?

·         How would the unmet needs affect the Pulmonary Embolism market dynamics and subsequent analysis of the associated trends?

 

Pulmonary Embolism Epidemiology Insights:

·         What are the disease risk, burden, and regional/ethnic differences of Pulmonary Embolism?

·         What is the historical and forecasted Pulmonary Embolism patient pool in the 7MM, and where can one observe the highest patient population and growth opportunities? 

·         What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

 

Current Treatment Scenario, Marketed Drugs, and Pulmonary Embolism Emerging Therapies

·         What are the current treatment guidelines and treatment options, in addition to approved therapies for Pulmonary Embolism in the US, Europe, and Japan?

·         What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Pulmonary Embolism therapies?

·         What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?

·         What are the clinical studies going on for Pulmonary Embolism and its status, along with the challenges faced?

 

Reasons to Buy

·         The patient-based Pulmonary Embolism market forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Pulmonary Embolism market.

·         Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Embolism in the US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

·         Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors.